INS and diabetes mellitus: Devices for the delivery of insulin may mimic how insulin is secreted and could potentially reduce diabetes-related complications (55, 56), but they do not address the underlying autoimmune pathology, nor is insulin release fully coupled to second-to-second fluctuating glucose levels.